A Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African Infants
Top Cited Papers
Open Access
- 13 December 2012
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 367 (24) , 2284-2295
- https://doi.org/10.1056/nejmoa1208394
Abstract
The candidate malaria vaccine RTS,S/AS01 reduced episodes of both clinical and severe malaria in children 5 to 17 months of age by approximately 50% in an ongoing phase 3 trial. We studied infants 6 to 12 weeks of age recruited for the same trial.This publication has 26 references indexed in Scilit:
- Pooled analysis of safety data from pediatric Phase II RTS,S/AS malaria candidate vaccine trialsHuman Vaccines, 2011
- First Results of Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African ChildrenNew England Journal of Medicine, 2011
- Design of a phase III multicenter trial to evaluate the efficacy of the RTS,S/AS01 malaria vaccine in children across diverse transmission settings in AfricaMalaria Journal, 2011
- Development of standardized laboratory methods and quality processes for a phase III study of the RTS, S/AS01 candidate malaria vaccineMalaria Journal, 2011
- Statistical methodology for the evaluation of vaccine efficacy in a phase III multi-centre trial of the RTS,S/AS01 malaria vaccine in African childrenMalaria Journal, 2011
- Assessment of severe malaria in a multicenter, phase III, RTS, S/AS01 malaria candidate vaccine trial: case definition, standardization of data collection and patient careMalaria Journal, 2011
- Impact of national malaria control scale-up programmes in Africa: magnitude and attribution of effectsMalaria Journal, 2010
- Defining Childhood Severe Falciparum Malaria for Intervention StudiesPLoS Medicine, 2007
- Rash including mucosal involvement: Case definition and guidelines for collection, analysis, and presentation of immunization safety dataVaccine, 2007
- Generalized convulsive seizure as an adverse event following immunization: case definition and guidelines for data collection, analysis, and presentationVaccine, 2003